|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.7300 - 1.8300|
|52 Week Range||1.4800 - 4.5000|
|Beta (3Y Monthly)||3.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTCQX: EMHTF) has received its initial cultivation license from Health Canada for its new organic cannabis growing facility in Metro Vancouver, BC. Tailor-made for Emerald to produce high-quality organic cannabis, the operation comprises two 78,000 square foot greenhouses and 12 acres (~500,000 square feet) of outdoor cultivation, with potential for an additional 12 acres.
OTCQX: EMHTF) is pleased that today the Government of Canada released the final regulatory framework for ingestibles and edibles. “The clarity of the final regulatory framework provides is important for Emerald in bringing our new product categories such as vape pens, ingestibles and edibles to market,” said Allan Rewak, VP Communications and Stakeholder Relations. The regulatory framework announced by Health Canada prohibits product forms that could be appealing to children and youth, combine alcohol or nicotine with cannabis and restrict production of infused cannabis products to dedicated licenced cannabis facilities approved by Health Canada.
OTCQX: EMHTF), a licensed producer of cannabis products for medical and recreational purposes, will participate in the Oppenheimer 19th Annual Consumer Growth and E-Commerce Conference on June 18, 2019 in Boston, MA. Bernie Hertel, Vice President of Finance and Communications, Emerald Health Sciences, will present a corporate overview and be available for 1x1 meetings.
OTCQX: EMHTF) reports that is has expanded its agreement to purchase harvested hemp flower and leaf, or hemp chaff, from Emerald Health Hemp Inc. (“EHH”) from 1,000 to 1,200 acres for 2019. EHH is a wholly owned subsidiary of Emerald Health Sciences Inc. and a related party of Emerald. Based on last year’s harvest, Emerald expects production from the 1,200 acres to be at least 270,000 kg of hemp chaff in 2019 with, conservatively, approximately 2% cannabidiol (“CBD”) content.
NEW YORK , June 4, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the launch of the OTCQX® Cannabis Index ...
VANCOUVER, British Columbia, June 03, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in multiple upcoming investment and.
VANCOUVER, British Columbia, May 31, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended.
NEW YORK, NY / ACCESSWIRE / May 31, 2019 / Emerald Health Therapeutics, Inc. (TSXVENTURE: EMHTF ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 31, 2019 ...
OTCQX: EMHTF) today announced that the vendors (the "Vendors") of Verdélite Sciences, Inc. and Verdélite Property Holdings, Inc. (collectively, "Verdélite") have received 2,129,707 shares of Emerald (the "Shares") in lieu of $7.5 million of the $22.5 million they were to receive as the final payment for their shares of Verdélite. Each Share was valued at $3.5216, the five-day volume-weighted average price of the common shares of Emerald on the TSX Venture Exchange (the "TSXV"), discounted 10%, calculated as of April 30, 2019. The agreement to receive shares in lieu of cash was previously announced by the Company on May 1, 2019.
OTCQX: EMHTF) has been appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its International Affairs Council on CBD and Hemp in ATACH’s engagement with the US Food & Drug Administration (FDA) regarding policy pertaining to CBD-containing products and associated cross-border trade. The FDA is slated to begin public consultation on May 31 to discuss potential pathways for CBD products to come to market in the US.
VICTORIA, British Columbia, May 22, 2019 -- Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) has appointed Sean Rathbone as Chief Operating Officer. Mr..
OTCQX: EMHTF) will host its first quarter 2019 financial results conference call on Friday, May 31st, 2019 at 10:30 a.m. ET. The Company will report its financial results for the first quarter ended March 31, 2019, after the market close on Thursday, May 30th, 2019. Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis.
OTCQX: EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received a Standard Processing License (the “Processing License”) from Health Canada for its 1.1 million square foot Delta 3 greenhouse facility. The Processing License permits Pure Sunfarms to extract and process cannabis at its Delta 3 facility, which will enable the development and manufacture of products derived from cannabis, including oils, other concentrates, and edibles. Pure Sunfarms will require an additional amendment to its sales license to sell cannabis oil, which it expects to be distributing to provincial/territorial distributors and private retailers by the fourth quarter of this year.
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...
VANCOUVER, British Columbia, May 17, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 6,000 40 ml units of its SYNC 25 CBD oil to the.
VANCOUVER, British Columbia, May 15, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in Cowen’s Toronto Cannabis Summit on May.
OTCQX: EMHTF) has been authorized by PEI Cannabis and Manitoba Liquor & Lotteries Corporation to supply Emerald-branded cannabis products into those provinces. “We are pleased to have the opportunity to serve additional provinces,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. Emerald’s cannabis supply is provided by its Verdélite indoor facility in Québec and Pure Sunfarms, its 50%-owned joint venture in British Columbia that is fully planted in its 1.03 million square foot greenhouse growing area.
Cannabis Stocks Sink as Market Sentiment DampensCannabis-sector ETFsThe cannabis sector has broadly fallen today as overall market sentiment has been dampened by US-China trade disputes. The Horizons Marijuana Life Sciences ETF (HMMJ) and the
Cannabis Sector Extended Its Losses Last Week(Continued from Prior Part)Cannabis stocks fellLast week, most of the stocks in the cannabis sector ended lower. The Horizons Marijuana Life Sciences ETF (HMMJ) fell ~1.2%, while the ETFMG Alternative
Emerald Health Therapeutics, Inc. (EMH.V) (“Emerald” or the “Company”) today announced that the vendors (the "Vendors") of Verdélite Sciences, Inc. and Verdélite Property Holdings, Inc. (collectively, "Verdélite") have elected to receive $7.5 million of the $22.5 million they were to receive as the final payment for their shares of Verdélite in shares of Emerald valued on the five-day volume-weighted average price of the common shares of Emerald on the TSX Venture Exchange, discounted 10%, calculated as of April 30, 2019. See the Company's news release dated May 2, 2018 for more details on the Verdélite acquisition. Emerald is to pay the remaining $15 million of the purchase price to the Vendors on or before May 30, 2019.
VANCOUVER, British Columbia, May 01, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the fourth quarter and.
Due to increasing political pressure and public discontent, the pharmaceutical industry, as well as healthcare in general, has gone volatile. For instance, the benchmark exchange-traded fund VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH) is down 4% since the beginning of March. A notable exception? GW Pharmaceuticals (NASDAQ:GWPH) stock.A few days ahead of its second quarter of fiscal 2019 earnings report, GW Pharmaceuticals stock is making a case for itself. A recent series of consecutive upswings should bring April returns back into positive territory. For the year, GWPH is looking at a gain of over 70% from December lows, well above its peers in the sector.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThen again, GWPH stock isn't quite like other pharmaceuticals. As I and my InvestorPlace colleagues mentioned, this is a marijuana company that does pharmaceuticals, not the other way around. Therefore, these shares don't have the same catalysts, nor the same headwinds as traditional sector players.And that has proven to be a good thing right now. With rising furor, politicians, particularly from the left, have expressed outrage at soaring drug prices. Not only that, there's popular Democrats support Senator Bernie Sanders' proposal, the "Medicare for All Act." * 7 A-Rated Stocks That Are Under $10 Since President Donald Trump isn't exactly winning hearts and minds, it's very possible that the Democrats will win the White House. If so, that doesn't bode well for pharmaceutical firms who have gone somewhat dependent on ridiculous drug pricing. However, GW Pharmaceuticals stock remains relatively untouched.Here's the thing: I don't expect this trend to change dramatically. In many ways, GWPH stock is the Amazon (NASDAQ:AMZN) of healthcare: their core ingredient, cannabis, is dirt cheap. Therefore, the underlying company has the ability to disrupt the drug-making industry like no one's business.That's a key consideration as we look toward Q2. GWPH Stock Should Fly on an Incident-free ReportFor its earnings report scheduled for May 6, I'm not expecting much fireworks. I believe that as long as management keeps the metrics in line with what we've seen with other marijuana companies, GWPH stock could fly.Consensus estimates peg earnings per share at a loss of 20 cents. This is right in the middle of individual estimates, which range from a loss of 25 cents to -15 cents. In the year-ago quarter, GWPH delivered a loss of 26 cents.On the revenue side, covering analysts are targeting $26 million. Individual estimates vary wildly here, ranging from $10.8 million to $37 million. In Q2 2018, the company rang up only $3.4 million.Based on everything we've seen from cannabis stocks, I expect GWPH to outperform in sales. More people are open to marijuana than ever before, which explains why sector players have enjoyed a revenue surge. However, I'd like the organization to at least hit its EPS target. As long as there are no ugly surprises here, GW Pharmaceuticals stock should take off.I'm not just saying that from a gut reaction perspective. Medical-cannabis competitors such as Emerald Health Therapeutics (OTCMKTS:EMHTF) and CannTrust (NYSE:CTST) have also performed well in the markets this year. The former is up 38.4% year-to-date, while the latter -- although incurring significant choppiness -- is up over 50% YTD.Plus, management can do a lot of good for GWPH stock with a strong narrative. Unlike companies specializing in recreational weed, GW Pharmaceuticals has the medicinal angle. It also has moral leverage.Essentially, the opioid crisis is an unintended byproduct of the traditional pharmaceutical industry. With its focus on natural treatments, GWPH stock has an edge that its mainstream rivals do not. Strong Tailwinds for GW Pharmaceuticals StockGiven the rancor in the pharmaceuticals space, I'm cautious on most names within the segment. But I have no such reservations for GWPH stock.As I mentioned earlier, this is a disruptive organization. The company is geared toward producing and cultivating a relatively cheap ingredient. In addition, management doesn't have to spend billions in research fine-tuning some exotic concoction in a high-tech laboratory. Instead, they just need to tweak an almost-turnkey product to better address specific symptoms.Better yet, cannabis has a long history of medicinal usage. It's virtually guaranteed that GWPH will avoid an epidemic like the current opioid crisis. Plus, with non-psychoactive cannabis products like cannabidiol, or CBD, gaining traction, management has further leverage and options.Finally, policies like the Medicare for All Act benefit GW Pharmaceuticals stock. Again, cannabis is cheap, and the company is built around this cheap product. It's dissimilar to mainstream drug-makers, who are accused of growing fat on ill-gotten gains, and are now facing a comeuppance. Under this backdrop, I believe GWPH deserves your serious consideration.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 7 A-Rated Stocks That Are Under $10 * 7 U.S. Shale Oil Stocks to Buy as Prices Rise * 10 Stocks to Sell Before They Give Back 2019 Gains * 10 Oversold Stocks to Run From Compare Brokers The post Disruptive GW Pharmaceuticals Is Exempt from Big Pharmaas Volatility appeared first on InvestorPlace.